AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)-pem: Interim safety data

Autor:	Joachim G.J.V. Aerts, Arnaud Scherpereel, M-J. Ahn, Jonah Kim, Antonio Chella, B. Lutiger, J. M. Trigo Perez, Anders Vikström, Radj Gervais, Achim Rittmeyer, Fabrice Barlesi, Vera Gorbunova, N. Ferrer
Rok vydání:	2011
Předmět:	Cisplatin Oncology Cancer Research medicine.medical_specialty Chemotherapy Bevacizumab business.industry medicine.medical_treatment medicine.disease Pemetrexed Internal medicine Interim medicine In patient Non small cell business Lung cancer medicine.drug
Zdroj:	Journal of Clinical Oncology. 29:7562-7562
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.7562
Popis:	7562 Background: 1L bev-based therapy followed by mtc bev offers clinical benefit over standard chemotherapy alone, as do either 1L cis-pem or mtc pem. AVAPERL1 is designed to investigate if contin...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a598f5f2c091c4667b1ed3cc45b59df3 https://doi.org/10.1200/jco.2011.29.15_suppl.7562 Zobrazit plný text záznamu